Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1205

1.

Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.

Koschmieder S, Gƶttgens B, Zhang P, Iwasaki-Arai J, Akashi K, Kutok JL, Dayaram T, Geary K, Green AR, Tenen DG, Huettner CS.

Blood. 2005 Jan 1;105(1):324-34. Epub 2004 Aug 26.

2.
4.
5.

Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.

Pear WS, Miller JP, Xu L, Pui JC, Soffer B, Quackenbush RC, Pendergast AM, Bronson R, Aster JC, Scott ML, Baltimore D.

Blood. 1998 Nov 15;92(10):3780-92.

6.

Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model.

Kometani K, Aoki M, Kawamata S, Shinozuka Y, Era T, Taniwaki M, Hattori M, Minato N.

Cancer Res. 2006 Oct 15;66(20):9967-76.

8.

Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice.

Gishizky ML, Johnson-White J, Witte ON.

Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3755-9.

9.
10.

BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice.

Voncken JW, Kaartinen V, Pattengale PK, Germeraad WT, Groffen J, Heisterkamp N.

Blood. 1995 Dec 15;86(12):4603-11.

11.

Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expressing hematopoietic cells: a transgenic study for blast crisis of human CML.

Honda H, Ushijima T, Wakazono K, Oda H, Tanaka Y, Aizawa Si, Ishikawa T, Yazaki Y, Hirai H.

Blood. 2000 Feb 15;95(4):1144-50.

13.

Oncogenic interaction between BCR-ABL and NUP98-HOXA9 demonstrated by the use of an in vitro purging culture system.

Mayotte N, Roy DC, Yao J, Kroon E, Sauvageau G.

Blood. 2002 Dec 1;100(12):4177-84. Epub 2002 Aug 1.

14.

Inducible expression of BCR/ABL using human CD34 regulatory elements results in a megakaryocytic myeloproliferative syndrome.

Huettner CS, Koschmieder S, Iwasaki H, Iwasaki-Arai J, Radomska HS, Akashi K, Tenen DG.

Blood. 2003 Nov 1;102(9):3363-70. Epub 2003 Jul 10.

15.

Chronic myelogenous leukemia: molecular and cellular aspects.

Pasternak G, Hochhaus A, Schultheis B, Hehlmann R.

J Cancer Res Clin Oncol. 1998;124(12):643-60. Review.

PMID:
9879825
16.

Engraftment of chronic myeloid leukemia in SCID mice.

Hoyle CF, Negrin RS.

Hematol Oncol. 1998 Sep;16(3):87-100.

PMID:
10235067
17.

Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies.

Warmuth M, Danhauser-Riedl S, Hallek M.

Ann Hematol. 1999 Feb;78(2):49-64. Review.

PMID:
10089019
18.

Model mice for BCR/ABL-positive leukemias.

Honda H, Hirai H.

Blood Cells Mol Dis. 2001 Jan-Feb;27(1):265-78.

PMID:
11358387
19.

Crk-associated substrate lymphocyte type regulates myeloid cell motility and suppresses the progression of leukemia induced by p210Bcr/Abl.

Seo S, Nakamoto T, Takeshita M, Lu J, Sato T, Suzuki T, Kamikubo Y, Ichikawa M, Noda M, Ogawa S, Honda H, Oda H, Kurokawa M.

Cancer Sci. 2011 Dec;102(12):2109-17. doi: 10.1111/j.1349-7006.2011.02066.x. Epub 2011 Sep 23.

20.

Disease progression in a murine model of bcr/abl leukemogenesis.

van Etten RA.

Leuk Lymphoma. 1993;11 Suppl 1:239-42. Review.

PMID:
8251903

Supplemental Content

Support Center